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Abstract
Objectives: Clinical trials for progressive neurodegenerative disorders such as
Alzheimer’s Disease and Amyotrophic Lateral Sclerosis have been hindered due
to the absence of effective pharmacodynamics markers to assay target engagement. We tested whether measurements of new protein production would be a
viable pharmacodynamics tool for RNA-targeted therapies. Methods: Transgenic animal models expressing human proteins implicated in neurodegenerative disorders – microtubule-associated protein tau (hTau) or superoxide
dismutase-1 (hSOD1) – were treated with antisense oligonucleotides (ASOs)
delivered to the central nervous system to target these human mRNA transcripts. Simultaneously, animals were administered 13C6-leucine via drinking
water to measure new protein synthesis after ASO treatment. Measures of new
protein synthesis and protein concentration were assayed at designated time
points after ASO treatment using targeted proteomics. Results: ASO treatment
lowered hTau mRNA and protein production (measured by 13C6-leucinelabeled hTau protein) earlier than total hTau protein concentration in transgenic mouse cortex. In the CSF of hSOD1 transgenic rats, ASO treatment lowered newly generated hSOD1 protein driven by decreases in newly synthesized
hSOD1 protein, not overall protein concentration, 30 days after treatment. At
later time points, decreases in newly generated protein were still observed after
mRNA lowering reached a steady state after ASO treatment. Interpretation:
Measures of newly generated protein show earlier pharmacodynamics changes
for RNA-lowering therapeutics compared with total protein concentration.
Early in ASO treatment, decreases in newly generated protein are driven by
changes in newly synthesized protein. Measuring new protein production in
CSF may be a promising early pharmacodynamics marker for RNA-targeted
therapeutics.

Introduction
The number of persons aged 65 and older globally is projected to triple by the year 2050,1 increasing the number
of people living with adult-onset, progressive neurodegenerative diseases in the population. There is a dire need to
develop novel therapeutics for these conditions, as current
FDA-approved drugs are not adequately effective, and no
treatments exist to reverse disease pathology. Despite promise of new therapies in preclinical models over the past
1492

30 years, these compounds have failed in Amyotrophic
Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD)
clinical trials at rates greater than 95% and 99%, respectively.2,3 One important way to improve the current treatment landscape is to focus on the development of novel
methods to determine whether a therapeutic has engaged
the intended target in human clinical trials.
A central hypothesis in neurodegenerative disease is that
the accumulation of misfolded proteins over time imparts
selective toxicity to specific neuronal populations, causing
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progressive neurodegeneration and manifestation of symptoms. This pathological misfolding of proteins in AD,4
ALS,5,6 Parkinson’s Disease (PD),7 and Huntington’s Disease (HD) 8 suggests that an approach to inhibit the production of toxic proteins within the cell may be an effective
therapy. One such approach includes lowering levels of
RNA to decrease protein translation using molecules such
as antisense oligonucleotides (ASOs) or small interfering
RNA (siRNA). ASOs are short, DNA-like molecules that
can be designed to selectively bind mRNA transcripts and
cause the catalytic destruction of particular mRNAs.9 ASOs
that lower mRNA levels and thus decrease translation of
proteins prone to misfolding show great promise in preclinical models of tauopathy,10 ALS,11–13 and HD,14 and are
relatively safe in humans.15 These promising data have led
to the launch of multiple clinical trials for ASOs in neurodegenerative diseases (NCT03225846, NCT02623699,
NCT02519036, NCT03186989).
For RNA-targeted therapeutics, it is crucial to establish
measurements that validate compound engagement with
its desired biological target, mRNA.16 However, it is
challenging to isolate mRNA from cerebrospinal fluid
(CSF), the primary biofluid available to assay target
engagement in the human central nervous system (CNS).
Because mRNA translation leads to the production of
new protein, protein-based biomarkers in CSF represent
an attractive avenue to pursue target engagement for
RNA-targeted therapeutics. In this study, we used nonradioactive, stable isotope labeling with an essential amino
acid 17,18 to identify inhibition of new protein production after ASO treatment. Using two preclinical models
of ASO targets in clinical trials for neurodegenerative
disease, we tested the hypotheses that stable isotope
labeling with 13C6-Leucine will: (1) identify pharmacodynamics at an earlier time point than protein concentration-based measures and (2) show measurable effects in
CSF to support translation of this assay approach from
animal models to human CNS. These results would support the use of new protein synthesis measurements in
clinical trials for RNA-lowering therapies in neurodegenerative diseases.

Methods
Transgenic animals
Transgenic mice expressing human tau (hTau) 19 (Jackson
Laboratories, Bar Harbor, ME) were maintained through
in-house breeding on a C57/Bl6 background. Transgenic
rats
expressing
human
superoxide
dismutase-1
(hSOD1WT) 20 were provided by Pak Chan (Stanford
University) and maintained through in-house breeding on
a Sprague-Dawley background. Genotyping was
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performed by PCR amplification of tail DNA (Table S1).
All breeding and experimental protocols were approved
by the Institutional Animal Care and Use Committee at
Washington University and conducted according to the
NIH Guide for Care and Use of Laboratory Animals.

Antisense oligonucleotides (ASOs)
ASOs that recruit RNase-H to degrade target mRNA and
an inactive, control ASO with no sequence specificity
were provided by Ionis Pharmaceuticals 10,21 (Fig. 1). All
ASOs were diluted in artificial CSF before use.

Surgical procedures
All animals were anesthetized by 2%–5% inhalant isoflurane, received constant isoflurane flow during the procedure, and were given an injection of bupivacaine prior to
incision. Following the surgical procedure, animals
received carprofen and were placed on a 37°C heating
pad for recovery.
For intracerebroventricular injections, 60-day-old hTau
transgenic mice received 300 lg of ASO at 1.0 mm M/
L, 0.3 mm A/P, 3.0 mm D/V from Bregma.22 Similarly, 120-day-old hSOD1 transgenic rats received 1000 lg
of ASO injected at 1.4 mm M/L, 0.4 mm A/P,
3.5 mm D/V from Bregma. For intrathecal ASO injection, 120-day-old hSOD1 transgenic rats received 1000 lg
of ASO between the L3 and L5 vertebrae.23 Both male
and female transgenic animals were used in these studies,
and researchers were blinded to the identity of treatment
throughout the duration of the experiment.
13

C6-Leucine oral labeling and tissue
collection

Methods for oral labeling in rodents with 13C6-Leucine
were described previously using unlabeled L-leucine or
labeled, 13C6-L-Leucine (Cambridge Isotope Laboratories,
Cambridge, MA) dissolved in water at 5 mg/mL.24 The
amount of 13C6-Leucine found in plasma, the precursor
for leucine found in the central nervous system,24 was
consistent in all experiments between groups (Figure S1).
At indicated time points after surgery, animals were
anesthetized with isoflurane and perfused with cold phosphate buffered saline (PBS) containing 0.03% heparin.
Before perfusion, CSF was extracted from rat cisterna
magna via a 23x¾” winged infusion butterfly needle (Terumo, Somerset, NJ). Blood was collected from mechanically ruptured vena cavae at the beginning of perfusion,
and the brain and spinal cord were harvested after perfusion. All samples were flash frozen in liquid nitrogen and
stored at 80°C before use.
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Figure 1. Antisense Oligonucleotides. Oligonucleotides containing phosphothioate backbone modifications: unmodified phosphodiester linkage
(red o), 20 -O-methoxyethylribose, (orange) and constrained ethyl (blue) groups. All cytosine residues are 50 methylcytosine.

mRNA isolation and analysis
mRNA isolation from flash-frozen tissues was performed
using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands). The EXPRESS One-Step Superscript qRT-PCR
Universal Kit (Invitrogen, Carlsbad, CA) was used for
reverse transcription and amplification of SOD1 and
MAPT mRNA transcripts. Comparative analysis by the
DDCt method, with GAPDH mRNA transcripts as an
internal control, was performed with the ABI PRISM
7500 Fast Real-Time System (Applied Biosystems, Waltham, MA) (Table S1).

N15 Recombinant Protein Standards
N15-labeled, recombinant hTau protein (isoform 2N4R
411) was a generous gift from Drs. Isabelle Huvent and
Guy Lippens (Universite des Sciences et Technologie de
Lille 1, France).
Recombinant hSOD1 was produced in Rosetta 2 E Coli
(Novagen) using an hSOD1 cDNA construct with an Nterminal GST tag subcloned into a pGEX4T-1 backbone.
Bacterial cultures were inoculated overnight in 15N-Celtone Complete Medium (Cambridge Isotope Laboratories,
Inc) with shaking at 37°C and induced with 1 mmol/L
IPTG for hSOD1 production. Protein was isolated by
incubation with 600 lL of glutathione sepharose 4B beads
(GE Healthcare) for 30 min, 1 unit of thrombin (Thrombin Cleavage Capture Kit, Millipore) for 20 h, and 30 lL
of streptavidin agarose for 30 min, performed at room
temperature. Samples were spun at 1000xg for 5 min, and
supernatant containing N15-labeled, hSOD1 recombinant
protein was collected.

Tissue homogenization, protein isolation,
and mass spectrometric analysis
hTau transgenic mouse brain tissue was homogenized
in PBS plus protease inhibitors (P8340; Sigma-Aldrich,
St. Louis, MO). Protein concentration of brain lysate
was determined by Pierce BCA assay (ThermoFisher
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Scientific, Waltham, MA). Total hTau was immunoprecipitated from 100 lg of tissue lysate using 30 lL of
CNBr-activated Sepharose beads (GE Healthcare, Chicago, IL) crosslinked to anti-hTau antibody (Tau 1
monoclonal, produced by Nicholas M. Kanaan, Michigan State University) at 3 mg antibody/g of beads in
1 mL PBS plus 1% NP-40, 5 mmol/L guanidine, and
protease inhibitors for 1.5 h at room temperature.
Before immunoprecipitation, 5 ng of N15-lableled hTau
was added to each sample. hTau was digested using
400 ng of sequencing-grade endoproteinase Trypsin
(Promega, Madison, WI) for 16 h at 37°C. Samples
were lyophilized and reconstituted in 25 lL of 2% acetonitrile/0.1% formic acid solution prior to liquid chromatography- quadrupole-orbitrap mass spectrometry
analysis (OrbiTrap Fusion, ThermoFisher).
hSOD1 was isolated from transgenic rat tissue or CSF
as described previously.24 Before immunoprecipitation,
200 ng of N15-labeled hSOD1 was added to each brain
or spinal cord sample, and 50 ng of N15 SOD1 was
added to CSF samples. Isolated hSOD1 was digested with
600 ng of sequencing-grade endoproteinase GluC in
25 lL of 50 mmol/L NaHCO3 buffer (pH 8.8) for 17 h at
room temperature. After solid phase extraction, samples
were lyophilized and resuspended in 25 lL 2% acetonitrile/0.1% formic acid solution prior to liquid chromatography-triple quadrupole mass spectrometry analysis (Xevo
TQ-S, Waters).
Newly synthesized protein rate was quantified by analyzing the incorporation of 13C6-Leucine into target proteins, indicated by the tracer-to-tracee ratio (TTR), by
comparing the area under the chromatogram curve for
SOD1 or tau peptides containing 13C6-Leucine or 12C6Leucine. Relative protein concentration was quantified by
measuring the ratio between the area under the curve of
protein immunoprecipitated from animal tissue and N15labeled recombinant protein (Tables S2 and S3). To
account for non-steady state conditions due to mRNA
lowering in this experiments, newly generated protein was
also analyzed by multiplying the relative protein concentration by protein TTR at each time point. For figure
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presentation, data for hTau is represented by the
TPSLPTPPTR peptide and data for hSOD1 is represented
by the GLHGFHVHE peptide, as all peptides measured
showed strong correlations within each sample (Fig. S2
and S3).
Plasma-free 13C6-Leucine abundance was analyzed from
TCA precipitation of 100 lL rat or mouse plasma via
capillary gas chromatography-negative chemical ionization-quadrupole mass spectrometry (Agilent) as described
previously.24

Statistical analysis
All statistical analyses were performed using Graphpad
Prism 7.0 (GraphPad Software). All hypothesis tests performed were two-sided assuming a normal distribution of
data. P < 0.05 was determined significant. Based on previous results,10,21 a cutoff of 50% target mRNA reduction
relative to the mean mRNA levels in inactive ASO-treated
animals was used as inclusion criteria for subsequent
analysis. In CSF analysis, samples were excluded if blood
contamination was visibly present or if the volume of
CSF collected was less than 75 lL. For relative quantification, samples were normalized to a single sample in each
experiment from the inactive ASO treatment group.
Quantitative results are expressed as mean difference and
95% confidence interval.

Results
Lowering new hTau production precedes
protein concentration changes after ASO
treatment
We performed ICV injection of an ASO targeting human
tau mRNA 10 in transgenic mice expressing the human
tau transgene (hTau mice) to understand lowering of tau
mRNA and total protein over time. To analyze newly
generated hTau protein, we administered 13C6-Leucine in
the drinking water at designated time points (Fig. 2A).
We organized the timing of ASO treatment, 13C6-Leucine
administration, and euthanasia to observe consistent,
maximum label incorporation of proteins within the CNS
at each time point analyzed. Preliminary studies showed
adequate labeling of hTau with 4 days of 13C6-Leucine
labeling (Fig. S4).
hTau ASO treatment lowered hTau mRNA in the cerebral cortex over time (Fig. 2B). As early as 2 days postinjection, hTau ASO treatment lowered hTau mRNA
levels by ~50% relative to inactive ASO, with further
change of hTau mRNA by ~72% by 23 days post-injection. hTau ASO treatment also decreased hTau protein
levels over time (Fig. 2C), with significant effects of ~32%
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observed at 23 days. The discrepancy between overall
mRNA lowering and protein lowering is consistent with
tau as a long-lived protein in the CNS.25
Using percent of 13C6-Leucine incorporation (TTR)
as a measure of new protein synthesis rate, hTau ASO
treatment lowered the rate of newly synthesized hTau
protein over time (Fig. 2D). We observed lowering of
newly generated hTau protein at 13 days after ASO
treatment by ~71%. Combined, these data suggest that
newly generated hTau protein is a reliable measure of
hTau ASO pharmacodynamics in central nervous system tissue, with newly generated hTau showing an earlier (13 vs. 23 days) and greater magnitude of effect
(71% vs. 32%) compared to hTau protein concentrations (Fig. 2E).

Lowering of 13C6-Leucine-labeled hSOD1
occurs in CSF after ASO treatment
hSOD1WT rats were treated with an ICV injection of
1000 lg hSOD1 ASO in the lateral ventricle and administered 13C6-Leucine in drinking water (Fig. 3A). Based on
previous measurements of hSOD1 half-life in these rats,24
and that lowering of CSF SOD1 after ASO treatment in
the G93A SOD1 transgenic rat model was observed at
42 days post-ASO treatment,26 we euthanized animals
30 days after treatment to assay hSOD1 total protein
levels and new hSOD1 protein production to identify
early ASO pharmacodynamics. hSOD1 ASO treatment
lowered hSOD1 mRNA globally within the CNS (Fig. 3B),
leading to overall hSOD1 protein lowering by ~62% in
cortex and ~40% in lumbar spinal cord (Fig. 3C). Similarly, we observed a decrease in new hSOD1 protein synthesis rate by ~34% in cortex and ~50% in lumbar spinal
cord (Fig. 3D). At this time point, lowering of both
hSOD1 protein concentration and new hSOD1 protein
synthesis rate drive overall decreases in newly generated
hSOD1 protein (Fig. 3E).
In CSF, hSOD1 treatment failed to lower hSOD1 protein concentration (Fig. 3F). However, SOD1 ASO treatment decreased 13C6-Leucine-labeled hSOD1 synthesis in
CSF by ~30% relative to the inactive ASO treatment
group (Fig. 3G). This effect of lowered 13C6-Leucinelabeled hSOD1 is specific to CSF, as we did not measure
any differences in peripheral hSOD1 protein in plasma
(Fig. S5). To test SOD1 protein concentration at a later
time point, we treated a separate cohort of animals without 13C6-Leucine labeling using the same ASO treatment
paradigm and analyzed CSF hSOD1 concentration at
50 days post-surgery (Fig. S6). Although we observed
lowering in hSOD1 mRNA throughout the CNS 50 days
post-ASO treatment (Fig. S6A), we did not observe
decreases in CSF hSOD1 protein concentration
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Figure 2. Lowered hTau protein synthesis precedes protein lowering after ASO treatment in hTau transgenic mice. (A) Experimental Design. hTau
transgenic mice received 300 lg of either hTau ASO or inactive ASO via intracerebroventricular injection and were labeled with13C6-Leucine
(13C6-Leu) at designated time points. (B) hTau mRNA levels in temporal cortex by qPCR. Compared to inactive ASO control, hTau ASO treatment
lowered hTau mRNA over time (2-Way ANOVA F3,24 = 10.04, P = 0.0145). hTau mRNA levels are significantly lowered as early as 2 days after
ASO treatment by 50% (95% CI: 34.8%, 66.9%), and remain lowered as late as 23 days post treatment by 72% (55.5%, 87.2%). (C) hTau
protein levels relative to N15-labeled recombinant standard in temporal cortex by LC-MS. hTau ASO treatment lowers hSOD1 protein over time
(2-Way ANOVA F3,24 = 3.374, P = 0.0349). This effect is observed at 23 days post-ASO treatment by 32% (0.05%, 64.0%). (D) Newly
synthesized 13C6-Leu-labeled hTau in temporal cortex by LC-MS. Values are measured as the tracer to trace ratio (TTR) of 13C6-Leu-labeled:12C6Leu-unlabeled hTau. Lowering of 13C6-Leu-labeled hTau is observed over time (2-Way ANOVA, F3,24 = 5.748, P = 0.0041), and as early as
13 days post-ASO treatment by 71% (95% CI: 29.4%, 123%). (E) Newly generated hTau protein measured by multiplying hTau protein
concentration and TTR to account for non-steady state conditions. **** P < 0.0001, *** P < 0.001, ** P < 0.01. n = 4 per treatment group per
time point. Error bars in figures represent standard error of the mean (SEM).

(Fig. S6B), suggesting an even longer incubation time
may be required to observe protein lowering in CSF.
Taken together, these data suggest changes in newly
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synthesized, 13C6-Leucine-labeled target proteins drive
early pharmacodynamics biomarker effects in the CSF
after ASO treatment (Fig. 3H).
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Figure 3. Lowered 13C6-Leucine-labeled hSOD1 observed in cerebrospinal fluid after ASO treatment in hSOD1 transgenic rats. (A) Experimental
Design. hSOD1 transgenic rats received 1000 lg of either hSOD1 ASO or inactive ASO via intracerebroventricular injection at designated time
points. (B) hSOD1 mRNA levels in the CNS by qPCR. hSOD1 mRNA levels are lowered globally in the CNS, with mRNA lowering of ~70% in
cortex and lumbar spinal cord and ~55% in cerebellum. (C) hSOD1 protein levels relative to N15-labeled recombinant standard in CNS cortex by
LC-MS. Lowering of hSOD1 protein is observed in both cortex at ~61% (95% CI: 41.9%, 81.3%) and lumbar spinal cord at ~40% (24.6%,
54.3%). (D) 13C6-Leucine (13C6-Leu) labeled hSOD1 in CNS by LC-MS. Values are measured as the tracer to trace ratio (TTR) of 13C6-Leulabeled:12C6-Leu-unlabeled hSOD1. Significant lowering of 13C6-Leu-labeled hSOD1 is observed in both cortex at ~34% (15.5%, 51.9%) and
lumbar spinal cord at ~50% (33.3%, 66.1%). (E) Newly generated hSOD1 protein measured by multiplying hSOD1 protein concentration and TTR
in tissues. (F) hSOD1 protein levels relative to N15-labeled recombinant standard in CSF by LC-MS. No changes in CSF hSOD1 protein levels were
observed (Student’s T-Test t = 0.448, P = 0.67). (G) 13C6-Leu labeled hSOD1 in CSF by LC-MS. Significant lowering of 13C6-Leu-labeled hSOD1 by
~30% (95% CI: 12.0%, 48.4%) observed relative to inactive ASO control (Student’s T Test t = 3.923, P = 0.0057). (H) Newly generated hSOD1
protein measured by multiplying hSOD1 protein concentration and TTR in CSF. One sample in inactive ASO group was excluded in CSF analysis
due to blood contamination during CSF collection. ****P < 0.0001, ***P < 0.001, **P < 0.01. Error bars in figures represent SEM.

A therapeutic window exists for newly
synthesized protein pharmacodynamics
To enhance the translational relevance of our findings, we
performed similar experiments in hSOD1 rats using
intrathecal ASO injection, the method of drug delivery
used in current clinical trials. We analyzed CNS tissue 10,
30, and 60 days after ASO treatment compared to inactive ASO control to better understand longitudinal
changes in hSOD1 protein (Fig. 4A). Contrary to hSOD1
ASO delivery by ICV injection, we observed differential
effects of hSOD1 mRNA lowering in CNS tissues after
intrathecal ASO injection. We observed a significant
hSOD1 mRNA decrease in the lumbar spinal cord over
time, with an average hSOD1 mRNA lowering at 60 days
by ~66%. However, hSOD1 treatment did not significantly lower hSOD1 mRNA in the cortex or cerebellum
over time (Fig. 4B). Because it is likely that SOD1 mRNA
will need to be lowered globally in the CNS to affect
SOD1 CSF levels, we focused on protein measurements in
the spinal cord, where we confidently documented mRNA
lowering.
To further understand the relationship between protein
lowering and lowering of hSOD1 synthesis rate after ASO
treatment, we analyzed hSOD1 protein in lumbar spinal
cord. hSOD1 ASO treatment decreased hSOD1 protein
levels across all time points measured, and treatment
effect was greatest at day 60, with 50% lowering of
hSOD1 protein (Fig. 4C). hSOD1 ASO treatment significantly lowered hSOD1 synthesis rate compared to inactive
ASO-treated animals (Fig. 4D). Interestingly, ASO treatment decreased the ratio of newly synthesized hSOD1 at
10 and 30 days by 40% and 45%, but there was no difference in 13C6-Leucine-labeled hSOD1 between groups at
day 60 despite lowering of total hSOD1 protein concentration. Therefore, at later time points, decreases in newly
generated hSOD1 protein by ASO treatment are driven
by overall lowering of protein concentration (Fig. 4E).
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Discussion
Our data show that, following treatment with a mRNA
lowering therapeutic, the lowering of newly synthesized
protein occurs before lowering of total protein concentration in tissue. Further, our findings indicate that labeled,
newly generated protein measures direct effects of protein
translation in the source tissues, which are not seen in
CSF protein concentrations at early time points. Given
the direct measurement of protein translation, labeling
protein production has higher sensitivity than protein
concentration-based measures for mRNA-lowering therapies. These studies suggest that identifying newly generated protein after ASO treatment is an effective proteinbased biomarker for assaying ASO target engagement
(Fig. 5).
Previous work supports the use of CSF protein concentration as a promising pharmacodynamics biomarker for
ASO therapy,26,27 and CSF SOD1 concentration is a secondary outcome measurement in an ongoing Phase I clinical trial (NCT0262399). However, a key limitation in the
use of CSF protein concentration as a measure of ASO
efficacy is the indirect mechanism informed by this assay.
ASOs inhibit the production of new protein, and measures of protein concentration also rely on transport to
CSF and the clearance of existing protein which may be
unaffected by ASO treatment. Especially in a rapidly progressing neurodegenerative disease such as ALS,28 it is
important to develop pharmacodynamics tools that identify direct mechanisms of action at early time points that
reflect the actual drug effect in the tissue of interest.
Our study design is translatable to humans, as stable
isotope labeling is safe and effective in measuring the
kinetics of proteins implicated in neurodegenerative disease within human CSF.17,18,24,25,29 Previous studies used
labeling with 13C6-Leucine to measure inhibition of amyloid beta peptide synthesis by a gamma secretase inhibitor
in human participants.30 However, these experiments
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Figure 4. A therapeutic window exists to observe lowered protein synthesis pharmacodynamics in the central nervous system. (A) Experimental
Design. hSOD1 transgenic rats received 1000 lg of either hSOD1 ASO or inactive ASO at designated time points via intrathecal injection. (B)
hSOD1 mRNA levels in the CNS by qPCR. hSOD1 mRNA levels are significantly lowered in spinal cord after hSOD1 ASO treatment (2 Way ANOVA
F2,39 = 10.91, P = 0.002), with a maximum lowering of ~66% (95% CI: 54.6%, 78.2%) 60 days post-treatment. No significant hSOD1 mRNA
lowering was observed in frontal cortex (two-Way ANOVA F2,40 = 1.48, P = 0.24) or cerebellum. (C) hSOD1 protein levels relative to N15-labeled
recombinant standard in lumbar spinal cord by LC-MS. Lowering of hSOD1 protein is observed over time (two-Way ANOVA F2,36 = 10.04,
P = 0.0004), with a maximum lowering by ~50% (95% CI: 42.5%, 79.8%) at Day 60. (D) 13C6-Leu labeled hSOD1 in CNS by LC-MS. Values are
measured as the tracer to trace ratio (TTR) of 13C6-Leu-labeled:12C6-Leu-unlabeled hSOD1. Significant lowering of newly synthesized hSOD1
observed after hSOD1 ASO Treatment (2 Way ANOVA F2,36 = 6.269, P = 0.0046). Lowering of 13C6-Leu-labeled hSOD1 is observed 10 and
30 days after ASO treatment by ~40–45% (30%, 88%). 60 days post ASO treatment, there was no difference in 13C6-Leu-labeled hSOD1
between groups (adjusted P value = 0.9976). (E) Newly generated hSOD1 protein measured by multiplying hSOD1 protein concentration and TTR
in tissues. ****P < 0.0001, ***P < 0.001, *P < 0.05. hSOD1 ASO: n = 5–10 per time point, Inactive ASO: n = 5–7 per time point. Error bars in
figures represent SEM.

were performed over a 36-hour time period, as the halflife of amyloid beta peptide is ~9 h in CSF.18 To our
knowledge, the results presented here are the first observations measuring new protein production of long-lived
protein targets in the CNS after therapeutic intervention.
Our approach can be directly applied to multiple RNAdirected strategies, such as siRNAs 31 and ASOs,32,33 that
target long-lived proteins in neurodegeneration for clinical trials. Besides its lowered protein production readout,
stable isotope labeling could be a powerful tool to examine increased protein production for therapeutic strategies
such as gene therapy 34 and splicing ASO treatments.35,36
Moreover, an understanding of protein kinetics using
stable isotope labeling can also inform on assays for therapies that target protein turnover, such as approaches that
activate protein clearance mechanisms 37 or promote
proper protein folding.38
Another advantage of our mass spectrometry-based
assay is the ability to specifically isolate mutant from
wild-type protein in patient populations. Many familial
forms of neurodegenerative diseases are caused by autosomal dominant mutations 31 and, thus, exhibit both
mutant and normal protein forms. However, it is currently unknown if mutant proteins display altered protein
kinetics compared with their wild type counterparts in
humans. Future studies in symptomatic, mutation-carrying patients are needed to characterize the half-life of
these target proteins in human CSF. Protein half-life measures will be crucial to determine the timing required to
observe pharmacodynamics effects in humans when
designing randomized-control clinical trials.
One limitation in this study is the inability to identify
target protein lowering in CSF after SOD1 ASO treatment. Without this effect, the relationship between lowered protein production and total protein concentration
cannot be determined in the biological fluid important
for human clinical trials. Previous data suggest this limitation may be due to the drug delivery paradigm in these
experiments. The current study used a single bolus
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injection of ASO in rodent models while previous studies
that observed total target protein lowering in CSF after
ASO treatment in nonhuman primate models were performed with multiple intrathecal ASO injections.10,21
Additionally, both transgenic animal models used here
express wild-type forms of the target protein. In previous
experiments, the G93A SOD1 rat model was used to
demonstrate hSOD1 protein lowering after ASO treatment 42 days after treatment.26 Our group 24 and others
39
have shown that mutant hSOD1 exhibits a shorter protein half-life in the CNS and CSF compared to WT
hSOD1. Taken together, these data suggest that CSF WT
hSOD1 protein concentration will occur at an even later
time point than 50 days after ASO treatment (Fig. S6).
Future investigation should also address these questions
in the presence of mutant protein implicated in disease,
as no pathological misfolding of either hSOD1 or hTau is
observed in the models employed here.19,20 Therefore,
continuing experiments in transgenic rat models or nonhuman primates should examine the relationship between
CSF protein half-life, protein concentration lowering, and
changes in new protein production over time after ASO
treatment, in addition to understanding how new protein
production in CSF changes in the presence of misfolded
proteins within the CNS.
In sum, the approach described here provides a framework for the development of assays that isolate the direct
mechanism of action of target engagement in neurodegenerative disease therapies, with the hope that such data
will lead to a higher success in clinical trial outcomes.
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Figure 5. A model of the interplay between new protein production and protein concentration pharmacodynamics in RNA-lowering treatment
strategies. (A) Normal protein turnover at steady state synthesis includes production (top arrow) and clearance (bottom arrow) rates in the CNS.
After ASO treatment, target ASO binds to target mRNA transcripts in the central nervous system. (B) Early after treatment, lowering in new
protein synthesis is observed due to lowering of target mRNA by ASO treatment. (C) In addition to lowering of new protein synthesis, proteins
present before 13C6-labeling are cleared at the rate of turnover or half-life. (D) mRNA lowering reaches steady state, resulting in a consistent
lowered protein synthesis rate. Protein clearance remains constant and faster than production, leading to a new lowered steady state protein
concentration detected at a later time and less magnitude.
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Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Figure S1. No differences in 13C6-Leucine oral labeling
between treatment groups in all experiments performed.
Plasma 13C6-Leucine values were analyzed in all samples
analyzed and compared between groups. A. hTau ICV
ASO plasma 13C6-Leucine at Day 23 post surgery, as seen
in Figure 2. No differences were observed (Student’s Ttest, P = 0.4496). B. hSOD1 ICV ASO plasma 13C6-Leucine at Day 30. No differences were observed (Student’s-T
test) C. hSOD1 IT ASO plasma 13C6-Leucine at all time
points assessed. No differences were observed (2-Way
ANOVA). Error bars in figures represent SEM.
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Figure S2. Correlation between all hTau peptides measured. Linear regression analysis comparing peptides
shows strong correlations exist between all three peptide
measurements. All p values < 0.0001 for each analysis.
Figure S3. Correlation between all hSOD1 peptides measured. Linear regression analysis comparing peptides
shows strong correlations exist between all peptide measurements. All P values < 0.0001 for each analysis.
Figure S4. Characterizing 13C6-Leucine incorporation into
hTau protein in hTauWT transgenic mice. hTau mice were
acclimated to leucine-free chow for 7 days, and labeled
with 5 mg/ml 13C6-leucine for 7 days. Mice were euthanized at 6 (n = 2), 10 (n = 3), 14 (n = 3), and 17
(n = 2) days post-end of label. Because of the high label
incorporation (nearly 15% TTR) and delayed appearance
of higher label incorporation after the end of the labeling
period 3-10 days after the end of labeling, subsequent
experiments reduced the label time to 4 days. Given maximal label incorporation at 6-10 days post-end of label,
all mice in the subsequent experiments were sacrificed at
5 days post-end of label. Error bars in figures represent
SEM.
Figure S5. No changes in peripheral hSOD1 after 1000 ug
hSOD1 ASO intracerebroventricular injection. A. hSOD1
protein levels relative to N15-labeled recombinant standard by LC-MS in plasma. No changes in plasma hSOD1
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protein levels were observed (Student’s T-test). B. 13C6Leu labeled hSOD1 in plasma by LC-MS. No changes in
plasma 13C6-Leu labeled hSOD1 was observed (Student’s
T-Test). Error bars in figures represent SEM.
Figure S6. No protein concentration pharmacodynamics
observed in CSF after 1000 ug hSOD1 ASO intracerebroventricular injection at 50 days post treatment. A.
hSOD1 mRNA levels in the CNS by qPCR. hSOD1
mRNA levels are significantly lowered in spinal cord and
frontal cortex by ~70% and 50%, respectively, after ASO
treatment relative to inactive ASO controls (Student’s Ttest). B. hSOD1 protein levels relative to N15-labeled
recombinant standard by LC-MS. No changes in CSF
hSOD1 protein levels were observed (Student’s T-test).
n = 5 for each treatment group, with one CSF sample
excluded from each group due to blood contamination.
**** P < 0.0001. Error bars in figures represent SEM.
Table S1. Primers and probes used for genotyping and
qPCR analysis of hTau (MAPT), hSOD1 (SOD1) and
mouse GAPDH (GAPDH) DNA.
Table S2. Transition ions used for hSOD1 tandem LCMS/MS. GLHGFHVHE peptide measurements were used
as representative data in figures.
Table S3. Transition ions used for hTau tandem LC-MS/
MS. TPSLPTPPTR peptide measurements were used as
representative data in figures.
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